Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/liv.15582 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimization and Validation of an HPLC Method for the Analysis of Carvedilol and Impurities.
ACS Omega
September 2025
Fuan Pharmaceutical Group Ningbo Team Pharmaceutical Co. Ltd, Ningbo 315201, China.
In this study, a liquid chromatography method was developed and validated for the accurate determination of carvedilol content while minimizing interference from impurity C and -formyl carvedilol and allowing precise impurity analysis. The reliability of the method was verified through key parameters such as linearity, precision, accuracy, and stability, ensuring robust performance in the detection and quantification of carvedilol and related impurities. And, the method was tested under varying conditions, including changes in the flow rate, initial column temperature, and mobile phase pH.
View Article and Find Full Text PDFErratum to 'Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis' [J Hepatol 83 (2025) 70-80].
J Hepatol
September 2025
Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain.
Role of Carvedilol in Inhibiting the Proliferation and Migration of Vascular Smooth Muscle Cells by Upregulating microRNA-145 Expression.
Physiol Res
August 2025
The First School of Clinical Medicine, Shanxi Medical University, Taiyuan, China,
The proliferation and migration of vascular smooth muscle cells (VSMCs) are the initial contributors to restenosis in patients undergoing percutaneous coronary intervention (PCI). MicroRNA-145 (miR-145) plays a significant role in this pathological process. Although carvedilol has been shown to inhibit VSMC proliferation and migration, the underlying mechanisms are not fully understood.
View Article and Find Full Text PDFAmelioration of intestinal ischemia reperfusion injury by carvedilol via regulation of eNOS/VEGF-A and inflammasome/ IL1β/ TNFα pathways.
Eur J Pharmacol
August 2025
Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Sohag University, Sohag, 82524, Egypt.
Intestinal ischemia reperfusion (IIR) is a life threating clinical disorder and a serious emergency case with high mortality rate. Finding ameliorative agents is a critical requisite to safeguard the tissue against its harmful effect not only on the intestine, but also on other organs especially the heart. Therefore, we tried in the current study to evaluate the role of carvedilol (CAR); an effective beta and alpha blocker with anti-oxidant, anti-apoptotic, anti-inflammatory properties and a metabolic regulator, on both cardiac and intestinal tissue in a model of IIR.
View Article and Find Full Text PDFFirst-Line β-Blocker Use for Hypertension in the Veterans Health Administration.
JAMA Netw Open
August 2025
Intermountain Healthcare Department of Population Health Sciences, Divisions of Health System Innovation and Research and Biostatistics, Spencer Fox-Eccles School of Medicine, University of Utah, Salt Lake City.
Importance: Starting in 2014, US guidelines have not recommended β-blockers for first-line treatment of hypertension in the absence of compelling indications due to their tolerability profile and inferior protection against stroke and mortality compared with other first-line agents. The prevalence and factors associated with this guideline-discordant practice are unknown.
Objective: To estimate the prevalence of and factors associated with first-line β-blocker use among those without compelling indications for a β-blocker.